Can I Use Targeted Therapy in RET-Positive mNSCLC in Pretreated Patients?
Guest: Justin Gainor, MD
\n\n\n \n
This program discusses rapidly evolving advances regarding early genomic profiling for NSCLC patients including detection of RET fusion/alterations and efficacy/safety of approved selective RET-targeted therapies for RET-positive NSCLC. Learners will be better prepared to integrate these options into individualized treatment plans in their clinical practice and address associated adverse events (AEs).